About: Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 October 2000

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в жовтні 2000 (uk) im Oktober 2000 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu n'ochobre de 2000 (ast) scientific article published on 01 October 2000 (en)
publication date	wds:Q73052904-71EEF3A6-1C7A-4F3A-8B40-374FC57206A7
publication date	2000-10-01 00:00:00Z (xsd:dateTime)
author name string	wds:Q73052904-05E8F88A-9749-4A3D-8F4F-3FAE06A36AD8 wds:Q73052904-17A36714-9EE7-47F5-AB13-A7F9707E99A2 wds:Q73052904-3310913A-1D27-48BC-B204-0EA950C348DA wds:Q73052904-4E9C648D-1402-4CDE-A2EE-E9941EACC86D wds:Q73052904-505FAB2E-1A63-49C8-9F78-EB667AA92EC3 wds:Q73052904-51F6DE22-3744-43DF-9A50-1F6CFC5FDC10 wds:Q73052904-594E66EC-3B3B-4B02-A2E4-CBB4F87FE8CF wds:Q73052904-5B09857F-0A86-441F-902A-2CD1F160276F wds:Q73052904-7BEF9D9A-3E41-4A53-BEBA-1FFAC43A21F4 wds:Q73052904-D87B5E02-F8F4-4B1C-9156-4FFA24DD69CA wds:Q73052904-DAB73960-6A4F-49FB-B479-38EFBDE778D4 wds:Q73052904-E6FC61F6-107F-4BC8-AB93-0D67631C8B87
author name string	Boyett JM Pui CH Ribeiro RC Campana D Behm FG Sandlund JT Rivera GK Coustan-Smith E Rubnitz JE Raimondi SC Sancho J Hancock ML
rdfs:label	Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia (en) Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia (nl)
skos:prefLabel	Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia (en) Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia (nl)
name	Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia (en) Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia (nl)
title	wds:Q73052904-A1ADC138-2897-478D-B5CB-2A2638886651
title	Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia (en)
page(s)	wds:Q73052904-B988E1EB-C097-4469-A2F8-7D83EB5CFA8D
page(s)	2691-2696
instance of	wds:Q73052904-2AB22B73-7C99-4AFF-BC7A-92490D887C1F
instance of	scholarly article
main subject	wds:Q73052904-CCC31898-DDF6-4CD7-927B-4385E040CF17
main subject	lymphoblastic leukemia
PubMed ID	wds:Q73052904-542B7A5A-59E0-47E8-A1B6-37A1A3EF3943
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/11023499
PubMed ID	11023499
published in	wds:Q73052904-5D0DB5AD-CBF1-4173-9658-403BE34382F6
published in	Blood
issue	wds:Q73052904-01CF09C7-B445-4006-BE25-A75B1521CCD4
volume	wds:Q73052904-BA7E515B-69C2-4383-845C-27DEC77364F1
issue	8
volume	96
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q73052904
is cites work of	Prognostic significance of monitoring leukemia-associated immunophenotypes by eight-color flow cytometry in adult B-acute lymphoblastic leukemia Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group Flow cytometric immunophenotypic assessment of T-cell clonality by Vβ repertoire analysis: detection of T-cell clonality at diagnosis and monitoring of minimal residual disease following therapy Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia Treating childhood acute lymphoblastic leukemia without cranial irradiation Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia Pharmacogenetics of outcome in children with acute lymphoblastic leukemia Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study A set of genes that regulate cell proliferation predicts treatment outcome in childhood acute lymphoblastic leukemia Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005. Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia Prognostic significance of minimal residual disease detected by a simplified flow cytometric assay during remission induction chemotherapy in children with acute lymphoblastic leukemia A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome Minimal residual disease in acute lymphoblastic leukemia A simplified minimal residual disease polymerase chain reaction method at early treatment points can stratify children with acute lymphoblastic leukemia into good and poor outcome groups Hematopoietic stem cell transplantation for leukemia Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232. Outcome of children with hypodiploid ALL treated with risk-directed therapy based on MRD levels New markers for minimal residual disease detection in acute lymphoblastic leukemia How and why minimal residual disease studies are necessary in leukemia: a review from WP10 and WP12 of the European LeukaemiaNet Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia Mitochondrial DNA in residual leukemia cells in cerebrospinal fluid in children with acute lymphoblastic leukemia Determination of ETV6-RUNX1 genomic breakpoint by next-generation sequencing NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following All A set of miRNAs that involve in the pathways of drug resistance and leukemic stem-cell differentiation is associated with the risk of relapse and glucocorticoid response in childhood ALL Relationship between minimal residual disease measured by multiparametric flow cytometry prior to allogeneic hematopoietic stem cell transplantation and outcome in children with acute lymphoblastic leukemia. Role of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: results of Children's Oncology Group trial P9906. Combination chemotherapy with clofarabine, cyclophosphamide, and etoposide in children with refractory or relapsed haematological malignancies. Impact of minimal residual disease, detected by flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia Progress of minimal residual disease studies in childhood acute leukemia Characterization of acute lymphoblastic leukemia subtypes in moroccan children Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children's Oncology Group Status of minimal residual disease testing in childhood haematological malignancies Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). Effective VCR/DEX pulse maintenance therapy in the KYCCSG ALL-02 protocol for pediatric acute lymphoblastic leukemia Role of minimal residual disease evaluation in leukemia therapy Establishment and validation of a standard protocol for the detection of minimal residual disease in B lineage childhood acute lymphoblastic leukemia by flow cytometry in a multi-center setting

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 172 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software